172 related articles for article (PubMed ID: 8620667)
1. The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.
Awni WM; Braeckman RA; Cavanaugh JH; Locke CS; Linnen PJ; Granneman GR; Dubé LM
Clin Pharmacokinet; 1995; 29 Suppl 2():112-24. PubMed ID: 8620667
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interactions between zileuton and prednisone.
Awni WM; Cavanaugh JH; Tzeng TB; Witt G; Granneman GR; Dubé LM
Clin Pharmacokinet; 1995; 29 Suppl 2():105-11. PubMed ID: 8620666
[TBL] [Abstract][Full Text] [Related]
3. Effect of zileuton on theophylline pharmacokinetics.
Granneman GR; Braeckman RA; Locke CS; Cavanaugh JH; Dubé LM; Awni WM
Clin Pharmacokinet; 1995; 29 Suppl 2():77-83. PubMed ID: 8620674
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic interaction between the lipoxygenase inhibitor MK-0591 and the cyclooxygenase inhibitor ibuprofen in man.
Depré M; Van Hecken A; Verbesselt R; De Lepeleire I; Schwartz J; Porras A; Larson P; Lin C; De Schepper PJ
Int J Clin Pharmacol Res; 1998; 18(2):53-61. PubMed ID: 9675622
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.
Rubin P; Dubé L; Braeckman R; Swanson L; Hansen R; Albert D; Carter G
Agents Actions Suppl; 1991; 35():103-16. PubMed ID: 1781415
[TBL] [Abstract][Full Text] [Related]
7. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
[TBL] [Abstract][Full Text] [Related]
8. Model-based analysis of thromboxane B₂ and prostaglandin E₂ as biomarkers in the safety evaluation of naproxen.
Sahota T; Sanderson I; Danhof M; Della Pasqua O
Toxicol Appl Pharmacol; 2014 Aug; 278(3):209-19. PubMed ID: 24667227
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans.
Awni WM; Hussein Z; Cavanaugh JH; Granneman GR; Dubé LM
Clin Pharmacokinet; 1995; 29 Suppl 2():92-7. PubMed ID: 8620677
[TBL] [Abstract][Full Text] [Related]
10. The effect of food on the pharmacokinetics of zileuton.
Awni WM; Cavanaugh JH; Witt G; Granneman GR; Dubé LM
Clin Pharmacokinet; 1995; 29 Suppl 2():62-6. PubMed ID: 8620672
[TBL] [Abstract][Full Text] [Related]
11. In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite.
Machinist JM; Kukulka MJ; Bopp BA
Clin Pharmacokinet; 1995; 29 Suppl 2():34-41. PubMed ID: 8620669
[TBL] [Abstract][Full Text] [Related]
12. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.
Weinblatt ME; Kremer JM; Coblyn JS; Helfgott S; Maier AL; Petrillo G; Henson B; Rubin P; Sperling R
J Rheumatol; 1992 Oct; 19(10):1537-41. PubMed ID: 1334515
[TBL] [Abstract][Full Text] [Related]
13. Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.
Samara E; Cavanaugh JH; Mukherjee D; Granneman GR
Clin Pharmacokinet; 1995; 29 Suppl 2():84-91. PubMed ID: 8620675
[TBL] [Abstract][Full Text] [Related]
14. The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa.
Treiber G; Wex T; Link A; Vieth M; Laufer S; Malfertheiner P
Aliment Pharmacol Ther; 2006 Jan; 23(1):155-67. PubMed ID: 16393293
[TBL] [Abstract][Full Text] [Related]
15. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
Awni WM; Braeckman RA; Locke CS; Dubé LM; Granneman GR
Clin Pharmacokinet; 1995; 29 Suppl 2():98-104. PubMed ID: 8620678
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine.
Awni WM; Cavanaugh JH; Leese P; Kasier J; Cao G; Locke CS; Dube LM
Eur J Clin Pharmacol; 1997; 52(1):49-54. PubMed ID: 9143867
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.
Awni WM; Hussein Z; Granneman GR; Patterson KJ; Dubé LM; Cavanaugh JH
Clin Pharmacokinet; 1995; 29 Suppl 2():67-76. PubMed ID: 8620673
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers.
Awni WM; Braeckman RA; Granneman GR; Witt G; Dubé LM
Clin Pharmacokinet; 1995; 29 Suppl 2():22-33. PubMed ID: 8620668
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers.
Wong SL; Awni WM; Cavanaugh JH; el-Shourbagy T; Locke CS; Dubé LM
Clin Pharmacokinet; 1995; 29 Suppl 2():9-21. PubMed ID: 8620676
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of zileuton in healthy young and elderly volunteers.
Braeckman RA; Granneman GR; Locke CS; Machinist JM; Cavannaugh JH; Awni WM
Clin Pharmacokinet; 1995; 29 Suppl 2():42-8. PubMed ID: 8620670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
